Urgent.News

What's breaking now, across thousands of outlets.

World

German Court Overturns Keytruda SC Sales Ban, Opening Door to European Expansion

The path to market entry in Germany, Europe’s largest pharmaceutical market, has opened for Keytruda SC, the subcutaneous formulation of the immuno-oncology drug developed by U.S.-based Merck (MSD), after a court overturned a preliminary injunction banning its sale. With both a German appellate cour

A key immuno-oncology drug, Keytruda SC, has won a legal battle in Germany, lifting a ban on its sale and paving the way for the drug's potential entry into Europe's largest pharmaceutical market. The decision, made by the Munich Higher Regional Court, reverses a preliminary injunction that had blocked the product's distribution and sale in Germany.

Merck, the U.S.-based company behind Keytruda SC, has received favorable rulings in both the German and U.S. patent disputes with rival Halozyme. In Germany, the appellate court's decision eliminates the preliminary restriction, while the U.S. Patent Trial and Appeal Board (PTAB) recently found the challenged claims in Halozyme's patents unpatentable.

Keytruda SC, a subcutaneous formulation of the IV version of the drug, uses Alteogen's subcutaneous formulation technology, ALT-B4. It offers a more convenient administration method compared to conventional IV infusions, reducing treatment time to just one to two minutes. Sales of Keytruda SC reached $830 million in the third quarter, marking a 79.3% increase from the previous quarter.

The expanded market access in Germany, the world's third-largest pharmaceutical market, could help MSD diversify its revenue base beyond the heavily concentrated U.S. market. The news also bodes well for Alteogen, which signed a licensing agreement with MSD in 2020 and has already reached its first sales milestone of $25 million in sales tied to Keytruda SC.

Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at businesskorea.co.kr →

More in World

More from Friday 20 November →